Skip to content

To study the effect of Panchakarma Essential in female patients with anxiety.

A Clinical Study to Evaluate the Safety and Efficacy of Panchakarma Essential in female patients with generalized anxiety disorder - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056234
Enrollment
30
Registered
2023-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Brahmi oil as per Panchakarma Essential: Dose - One liter of Panchakarma Essential Route - Topical Frequency - Once a week for seven weeks Control Intervention1: Standard Practice of P

Sponsors

Mprex Healthcare Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female subjects 30-60 years of age will be included.2.Female subjects with no history of allergy to oils.3.Be willing to refrain from taking any medication during or before the study for the said indication. 4.An ambulatory female subject can provide verbal and written consent and is ready to comply with all study procedures.

Exclusion criteria

Exclusion criteria: 1. Female subjects with Depression, Social phobias, Hypertension, Cardiac diseases, Epilepsy, Asthma, Hyperthyroidism, Alcoholics, and Drug addicts 2. History of psychiatric disorder that may impair the ability of subjects to provide written informed consent.

Design outcomes

Primary

MeasureTime frame
1. To study the efficacy of Panchakarma Essential in female patients with generalized anxiety disorders. 2. To study the changes in the Visual analogue & mood assessment scores. Timepoint: 7 sittings once a week (i.e. for 2 months)

Secondary

MeasureTime frame
To assess the improvement in the Quality of life of a patientTimepoint: 7 sittings once a week (i.e. for 2 months)

Countries

India

Contacts

Public ContactDr Vaishnavi Patil

Mprex Healthcare Pvt. Ltd.

vaishnavi@mprex.in9834585994

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026